NFE2L2 and non-small cell lung carcinoma: Of note, the FDA-approved CsA, as a chemical inducer of NRF2 degradation, exhibits a significantly synergistic anti-cancer effect when administered as a combination therapy alongside the clinical glutaminase inhibitor CB-839 in NRF2-hyperactivated NSCLC.